Molecular Partners AG (MOLN.SW)
CHF 3.22
(0.16%)
CHF 3.22
(0.16%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -40.8 Million CHF | -129.4% |
| 2022 | 138.8 Million CHF | 399.23% |
| 2021 | -46.38 Million CHF | 0.73% |
| 2020 | -46.73 Million CHF | -102.17% |
| 2019 | -23.11 Million CHF | -340.54% |
| 2018 | -5.24 Million CHF | -339.15% |
| 2017 | 2.19 Million CHF | -74.09% |
| 2016 | 8.46 Million CHF | -69.7% |
| 2015 | 27.95 Million CHF | 5.67% |
| 2014 | 26.45 Million CHF | -15.2% |
| 2013 | 31.19 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -11.36 Million CHF | -4.49% |
| 2024 Q3 | 681 Thousand CHF | 105.9% |
| 2024 Q2 | -11.53 Million CHF | -1.5% |
| 2023 Q2 | -11.21 Million CHF | -16.3% |
| 2023 Q1 | -9.64 Million CHF | -1.34% |
| 2023 Q4 | -10.87 Million CHF | -19.99% |
| 2023 Q3 | -9.06 Million CHF | 19.18% |
| 2023 FY | -40.8 Million CHF | -129.4% |
| 2022 Q3 | -9.15 Million CHF | -1012.88% |
| 2022 Q1 | 158.3 Million CHF | 1582.27% |
| 2022 FY | 138.8 Million CHF | 399.23% |
| 2022 Q4 | -9.51 Million CHF | -3.91% |
| 2022 Q2 | -823 Thousand CHF | -100.52% |
| 2021 Q1 | -15.34 Million CHF | 7.68% |
| 2021 Q2 | -12.2 Million CHF | 20.48% |
| 2021 FY | -46.38 Million CHF | 0.73% |
| 2021 Q4 | -10.68 Million CHF | -30.96% |
| 2021 Q3 | -8.15 Million CHF | 33.18% |
| 2020 Q2 | -8.06 Million CHF | 15.6% |
| 2020 Q3 | -12.48 Million CHF | -54.73% |
| 2020 FY | -46.73 Million CHF | -102.17% |
| 2020 Q1 | -9.55 Million CHF | -8.16% |
| 2020 Q4 | -16.62 Million CHF | -33.18% |
| 2019 Q2 | -2.72 Million CHF | 0.0% |
| 2019 FY | -23.11 Million CHF | -340.54% |
| 2019 Q4 | -8.83 Million CHF | 0.0% |
| 2019 Q3 | -8.83 Million CHF | -224.83% |
| 2019 Q1 | -2.72 Million CHF | 72.2% |
| 2018 Q4 | -9.78 Million CHF | 0.0% |
| 2018 FY | -5.24 Million CHF | -339.15% |
| 2018 Q1 | -4.13 Million CHF | -83.31% |
| 2018 Q2 | -4.13 Million CHF | 0.0% |
| 2018 Q3 | -9.78 Million CHF | -136.61% |
| 2017 Q3 | -2.25 Million CHF | 71.88% |
| 2017 FY | 2.19 Million CHF | -74.09% |
| 2017 Q4 | -2.25 Million CHF | 0.0% |
| 2017 Q2 | -8.02 Million CHF | -63.76% |
| 2017 Q1 | -4.9 Million CHF | -7.81% |
| 2016 Q3 | -3 Million CHF | 23.02% |
| 2016 Q4 | -4.54 Million CHF | -51.5% |
| 2016 FY | 8.46 Million CHF | -69.7% |
| 2016 Q1 | -700 Thousand CHF | -200.29% |
| 2016 Q2 | -3.89 Million CHF | -456.71% |
| 2015 Q3 | 4 Million CHF | -13.15% |
| 2015 Q2 | 4.6 Million CHF | 283.79% |
| 2015 FY | 27.95 Million CHF | 5.67% |
| 2015 Q1 | 1.2 Million CHF | 168.84% |
| 2015 Q4 | 698 Thousand CHF | -82.55% |
| 2014 Q4 | -1.74 Million CHF | -187.16% |
| 2014 Q3 | 2 Million CHF | -60.17% |
| 2014 Q2 | 5.02 Million CHF | 0.0% |
| 2014 Q1 | 5.02 Million CHF | -24.07% |
| 2014 FY | 26.45 Million CHF | -15.2% |
| 2013 Q2 | 7.79 Million CHF | 0.0% |
| 2013 FY | 31.19 Million CHF | 0.0% |
| 2013 Q1 | 7.79 Million CHF | 0.0% |
| 2013 Q4 | 6.61 Million CHF | -15.2% |
| 2013 Q3 | 7.79 Million CHF | 0.0% |
| 2012 Q4 | 7.79 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Addex Therapeutics Ltd | -5.31 Million CHF | -667.276% |
| BB Biotech AG | -199.56 Million CHF | 79.553% |
| Basilea Pharmaceutica AG | 130.84 Million CHF | 131.188% |
| Evolva Holding SA | -2.58 Million CHF | -1480.036% |
| Idorsia Ltd | 145.23 Million CHF | 128.096% |
| Kuros Biosciences AG | 22.87 Million CHF | 278.41% |
| Relief Therapeutics Holding AG | -10.85 Million CHF | -275.78% |
| Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | 140.993% |